Profile
Marc S.
Rudoltz worked as a Principal at Enzon Pharmaceuticals, Inc., a Senior Global Clinical Leader at Novartis Oncology, Inc., a Chief Medical Officer at Viamet Pharmaceuticals, Inc., GPC Biotech, Inc., Constellation Pharmaceuticals, Inc., and Deciphera Pharmaceuticals, Inc. He also worked as a Chief Medical Officer at Viamet Pharmaceuticals Corp.
In terms of education, Rudoltz earned an undergraduate degree from Massachusetts Institute of Technology and a doctorate from SUNY Upstate Medical University.
Former positions of Marc S. Rudoltz
| Companies | Position | End |
|---|---|---|
| TANGO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2022-11-09 |
| CONSTELLATION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
| DECIPHERA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
| ENZON PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
GPC Biotech, Inc.
 GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA. | Corporate Officer/Principal | - |
Training of Marc S. Rudoltz
| Massachusetts Institute of Technology | Undergraduate Degree |
| SUNY Upstate Medical University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ENZON PHARMACEUTICALS, INC. | Health Technology |
| DECIPHERA PHARMACEUTICALS, INC. | Health Technology |
| TANGO THERAPEUTICS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Health Technology |
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Health Technology |
Viamet Pharmaceuticals Corp.
 Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Health Technology |
GPC Biotech, Inc.
GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA. | Retail Trade |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Marc S. Rudoltz
